In a report released today, Chad Messer from Needham reiterated a Buy rating on NextCure (NXTC), with a price target of $30.00. The company’s shares closed last Friday at $9.90, close to its 52-week low of $7.91.
According to TipRanks.com, Messer is a 5-star analyst with an average return of 10.2% and a 47.0% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NextCure with a $30.00 average price target.
See today’s analyst top recommended stocks >>
Based on NextCure’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $14.51 million. In comparison, last year the company earned revenue of $1.4 million and had a GAAP net loss of $8.22 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD.